Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Melanoma drug 'fast-tracked'
West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.
West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.
Nexavar was approved last year for treatment of renal cell carcinoma.
Related Videos
Related Content
